Results 31 to 40 of about 9,516,409 (390)

Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?

Biomedicines, 2022
(1) Background: We explored, for the first time, the contribution of angiogenic T cells (TAng) in interstitial lung disease associated to autoimmune disease (AD-ILD+) as potential biomarkers of the disease, evaluating their role in the underlying ...
Verónica Pulito-Cueto, Sara Remuzgo-Martínez, Fernanda Genre, Belén Atienza-Mateo, Víctor M. Mora-Cuesta, David Iturbe-Fernández, Leticia Lera-Gómez, Javier Rodriguez-Carrio, Diana Prieto-Peña, Virginia Portilla, Ricardo Blanco, Alfonso Corrales, Oreste Gualillo, José M. Cifrián, Raquel López-Mejías, Miguel A. González-Gay   +15 more
doaj   +1 more source

2022 EULAR points to consider for remote care in rheumatic and musculoskeletal diseases

Annals of the Rheumatic Diseases, 2022
Background Remote care and telehealth have the potential to expand healthcare access, and the COVID-19 pandemic has called for alternative solutions to conventional face-to-face follow-up and monitoring.
A. de Thurah, P. Bosch, A. Marques, Y. Meissner, C. Mukhtyar, J. Knitza, A. Najm, N. Østerås, T. Pelle, L. Knudsen, H. Šmucrová, F. Berenbaum, M. Jani, R. Geenen, M. Krusche, P. Pchelnikova, Savia de Souza, S. Badreh, D. Wiek, S. Piantoni, J. Gwinnutt, C. Duftner, H. Canhão, L. Quartuccio, N. Stoilov, Yeliz Prior, J. Bijlsma, A. Zabotti, T. Stamm, C. Dejaco   +29 more
semanticscholar   +1 more source

OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Rheumatology, 2022
Background/Aims People with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMDs) were excluded from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccine clinical development programmes; therefore, concerns regarding the
P. Machado, S. Lawson-Tovey, A. Strangfeld, E. Mateus, K. Hyrich, L. Gossec, L. Carmona, A. Rodrigues, B. Raffeiner, C. Duarte, E. Hachulla, E. Veillard, E. Straková, G. Burmester, G. Yardimci, J. Gómez-Puerta, J. Zepa, L. Kearsley‐Fleet, L. Trefond, M. Cunha, M. Mosca, M. Cornalba, M. Soubrier, N. Roux, O. Brocq, P. Durez, R. Conway, T. Goulenok, J. Bijlsma, I. McInnes, X. Mariette   +30 more
semanticscholar   +1 more source

Incidence of Unrecognized Incidental Durotomy during Surgery for Malignant Spinal Tumor

Spine Surgery and Related Research, 2020
Introduction: Cerebral spinal fluid leak from durotomy is a well-known risk with spinal surgeries. The aim of this study is to identify the incidence of unrecognized incidental durotomy during posterior surgery for spinal metastases and its risk factors.
Takuma Koyama, Shurei Sugita, Takahiro Hozumi, Masanori Fujiwara, Kiyofumi Yamakawa, Tomotake Okuma, Takahiro Goto   +6 more
doaj   +1 more source

Lived experiences of informal caregivers of people with chronic musculoskeletal pain: a systematic review and meta-ethnography [PDF]

, 2021
BACKGROUND: People with chronic pain often seek support from friends and family for everyday tasks. These individuals are termed informal caregivers. There remains uncertainty regarding the lived experiences of these people who care for individuals with ...
Bowlby J., Bronfenbrenner U, GBD, Major CH, Mease P., Merskey H, Sofaer-Bennett B   +6 more
core   +1 more source

American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Arthritis & Rheumatology, 2022
To provide guidance to rheumatology providers on the use of COVID‐19 vaccines for patients with rheumatic and musculoskeletal diseases (RMDs).
J. Curtis, S. Johnson, Dona Anthony, R. Arasaratnam, L. Baden, A. Bass, C. Calabrese, E. Gravallese, R. Harpaz, Andrew T. Kroger, R. Sadun, Amy S. Turner, E. Williams, T. Mikuls   +13 more
semanticscholar   +1 more source

Optimal treatment strategies for musculoskeletal diseases [PDF]

, 2013
This paper presents a model which aims to find an optimal treatment time for patients with musculoskeletal diseases. The stochastic dynamic programming model presented is based on minimizing expected costs given a stochastic processes for cure with ...
Haugen, Kjetil K.
core   +1 more source

Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group

Aging Clinical and Experimental Research, 2022
Vitamin D is a key component for optimal growth and for calcium–phosphate homeostasis. Skin photosynthesis is the main source of vitamin D. Limited sun exposure and insufficient dietary vitamin D supply justify vitamin D supplementation in certain age ...
T. Chevalley, M. Brandi, K. Cashman, E. Cavalier, N. Harvey, S. Maggi, C. Cooper, N. Al-Daghri, O. Bock, O. Bruyère, M. Rosa, B. Cortet, A. Cruz-Jentoft, A. Cherubini, B. Dawson-Hughes, R. Fielding, N. Fuggle, P. Halbout, J. Kanis, J. Kaufman, O. Lamy, A. Laslop, María Concepción Prieto Yerro, R. Radermecker, J. Thiyagarajan, Thierry Thomas, N. Veronese, M. de Wit, J. Reginster, R. Rizzoli   +29 more
semanticscholar   +1 more source

Appropriateness and efficacy of Spa therapy for musculoskeletal disorders. A Delphi method consensus initiative among experts in Italy. [PDF]

, 2017
OBJECTIVE: The aim of the study was to identify the main aspects concerning appropriateness and efficacy of Spa therapy for musculoskeletal pathologies. METHODS: A committee of 8 experts from Italian universities, public hospitals, territorial services,
BERNETTI, ANDREA, Brignoli, O, Coclite, D, FRAIOLI, Antonio, Masiero, S, Napoletano, A, PAOLONI, Marco, Quirino, N, Rengo, F, Ruosi, C, SANTILLI, VALTER, Viora, U, Vitale, M   +12 more
core   +1 more source

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Annals of the Rheumatic Diseases, 2022
Objective To develop EULAR points-to-consider for therapeutic drug monitoring (TDM) of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases (RMDs).
C. Krieckaert, A. V. van Tubergen, J. Gehin, B. Hernández-Breijo, G. le Mélédo, A. Balsa, P. Böhm, S. Čučnik, O. Elkayam, G. Goll, F. Hooijberg, M. Jani, P. Kiely, Neil McCarthy, D. Mulleman, V. Navarro-Compán, K. Payne, M. Perry, C. Plasencia-Rodríguez, S. Stones, S. W. Syversen, A. de Vries, Katherine M Ward, G. Wolbink, J. Isaacs   +24 more
semanticscholar   +1 more source